Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNMT | P11086 | 2/20 | 0.76 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.76 |
| ▸ | SIGMAR1 | Q99720 | 9/20 | 0.67 |
| ▸ | IGF1R | P08069 | 1/20 | 0.58 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.58 |
| ▸ | IDO1 | P14902 | 3/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL14829816 | 0.98 | PNMT (0.73) | PNMTTAAR1SIGMAR1IGF1RALOX15 | |
| SCHEMBL4714764 | 0.94 | PNMT (0.73) | PNMTTAAR1SIGMAR1IGF1RALOX15 | |
| SCHEMBL31497388 | 0.94 | PNMT (0.73) | PNMTTAAR1SIGMAR1IGF1RALOX15 | |
| SCHEMBL11324805 | 0.92 | PNMT (0.70) | PNMTTAAR1SIGMAR1IGF1RALOX15 | |
| SCHEMBL11332031 | 0.92 | PNMT (0.70) | PNMTTAAR1SIGMAR1IGF1RALOX15 | |
| SCHEMBL11331998 | 0.92 | PNMT (0.70) | PNMTTAAR1SIGMAR1IGF1RALOX15 | |
| SCHEMBL11327503 | 0.92 | PNMT (0.70) | PNMTTAAR1SIGMAR1IGF1RALOX15 | |
| SCHEMBL11332990 | 0.92 | PNMT (0.70) | PNMTTAAR1SIGMAR1IGF1RALOX15 | |
| SCHEMBL11332028 | 0.92 | PNMT (0.70) | PNMTTAAR1SIGMAR1IGF1RALOX15 | |
| SCHEMBL11338042 | 0.92 | PNMT (0.70) | PNMTTAAR1SIGMAR1IGF1RALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 104 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2847174-B1 | PYRIMIDINONE CARBOXAMIDES AS INHIBITORS OF ENDOTHELIAL LIPASE | BRISTOL MYERS SQUIBB CO (US) | 2017-05-17 | — | — | EP | disclosed |
| EP-2847174-B1 | PYRIMIDINONE CARBOXAMIDES AS INHIBITORS OF ENDOTHELIAL LIPASE | BRISTOL MYERS SQUIBB CO (US) | 2017-05-17 | — | — | EP | disclosed |
| EP-2760834-B1 | PYRIDINEDIONE CARBOXAMIDE INHIBITORS OF ENDOTHELIAL LIPASE | BRISTOL MYERS SQUIBB CO (US) | 2016-11-16 | — | — | EP | disclosed |
| EP-2760834-B1 | PYRIDINEDIONE CARBOXAMIDE INHIBITORS OF ENDOTHELIAL LIPASE | BRISTOL MYERS SQUIBB CO (US) | 2016-11-16 | — | — | EP | disclosed |
| US-9394260-B2 | Pyrimidinone carboxamide inhibitors of endothelial lipase | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-07-19 | — | — | US | disclosed |
| US-9394260-B2 | Pyrimidinone carboxamide inhibitors of endothelial lipase | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-07-19 | — | — | US | disclosed |
| US-9394260-B2 | Pyrimidinone carboxamide inhibitors of endothelial lipase | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-07-19 | — | — | US | disclosed |
| EP-2760829-B1 | PYRROLINONE CARBOXAMIDE COMPOUNDS USEFUL AS ENDOTHELIAL LIPASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2016-05-18 | — | — | EP | disclosed |
| EP-2760829-B1 | PYRROLINONE CARBOXAMIDE COMPOUNDS USEFUL AS ENDOTHELIAL LIPASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2016-05-18 | — | — | EP | disclosed |
| US-9249096-B2 | Pyrrolinone carboxamide compounds useful as endothelial lipase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-02-02 | — | — | US | disclosed |
| US-20040138227-A1 | Phenoxypropylamine compounds | NISHIYAMA AKIRA | 2004-07-15 | — | — | US | disclosed |
| US-20040110804-A1 | HIV integrase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2004-06-10 | — | — | US | disclosed |
| US-6720320-B2 | ANTISEROTONINE AGENTS | MITSUBISHI PHARMA CORPORATION (JP) | 2004-04-13 | — | — | US | disclosed |
| US-20020111358-A1 | Phenoxypropylamine compounds | MITSUBISHI PHARMA CORPORATION (JP) | 2002-08-15 | — | — | US | disclosed |
| EP-1188747-A1 | PHENOXYPROPYLAMINE COMPOUNDS | Mitsubishi Pharma Corporation (JP) | 2002-03-20 | — | — | EP | disclosed |
| EP-0525360-B1 | Novel phenylacetamide derivatives and processes for the preparation thereof | KOREA RES INST CHEM TECH (KR) | 1998-03-25 | — | — | EP | disclosed |
| US-5242944-A | Analgesics or antiinflammatory agents | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 1993-09-07 | — | — | US | disclosed |
| EP-0525360-A2 | Novel phenylacetamide derivatives and processes for the preparation thereof | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 1993-02-03 | — | — | EP | disclosed |
| EP-0002721-B1 | PROCESS FOR PREPARING HYDRAZINES | BAYER AG (DE) | 1981-09-02 | — | — | EP | disclosed |
| EP-0002721-A2 | Process for preparing hydrazines | BAYER AG (DE) | 1979-07-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040138227-A1 | Phenoxypropylamine compounds | HTR1A, HTR1D, HTR5A | PNMT 20/4885TAAR1 57/4885SIGMAR1 50/4885 |
| US-20040110804-A1 | HIV integrase inhibitors | CDKN1A, SAMHD1, CTCF | PNMT 2181/4885TAAR1 4746/4885SIGMAR1 4036/4885 |
| US-20020111358-A1 | Phenoxypropylamine compounds | HTR1A, HTR1D, HTR5A | PNMT 20/4885TAAR1 57/4885SIGMAR1 50/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.